Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Nov 20, 2024Closes
Nov 18, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Education, Health
Eligible applicants: State governments, Public and State controlled institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Special district governments, City or township governments, For profit organizations other than small businesses, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, County governments, Native American tribal organizations (other than Federally recognized tribal governments), Independent school districts, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal governments (Federally recognized)
Description
This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.